DeepDrugDiscovery identifies blood–brain barrier permeable autophagy enhancers for Alzheimer’s disease

Dysfunctional autophagy, a key cellular cleaning process, is a key driver of brain ageing and neurodegenerative diseases such as Alzheimer’s disease (AD). However, developing effective treatments by enhancing autophagy has been challenging, as most known compounds act through the broad mTOR pathway, risking side effects, and few can effectively penetrate the brain. To address this, we developed DeepDrugDiscovery—a mechanism-aware, AI-powered screening platform incorporating ADMET and blood–brain barrier penetrability predictions. Here we show that this platform successfully identified novel, mTOR-independent autophagy enhancers, with two lead compounds demonstrating an ability to cross the blood–brain barrier, clear AD-related protein aggregates and restore memory function in worm and mouse AD models. By releasing DeepDrugDiscovery as an open-source, modular tool, we offer a user-friendly AI platform that enables customized therapeutic screening. Our work establishes a scalable, AI-driven pipeline that integrates cross-species validation to rapidly discover mechanism-based therapeutics for diseases with high unmet medical need. DeepDrugDiscovery is an AI-powered screening platform incorporating ADMET and blood–brain barrier penetrability predictions to successfully identify mTOR-independent autophagy enhancers that can cross the blood–brain barrier for Alzheimer’s disease therapy.